MULTIPLE MYELOMA IN RELAPSE
Clinical trials for MULTIPLE MYELOMA IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA IN RELAPSE trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Tough-to-Treat myeloma: Triple-Drug combo enters phase 2
Disease control Recruiting nowThis study tests a new drug called inobrodib combined with two standard medicines (pomalidomide and dexamethasone) in 100 adults whose multiple myeloma has come back or no longer responds to available therapies. The goal is to see how well the combination shrinks or controls the …
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated May 26, 2026 05:41 UTC
-
Engineered immune cells take on Hard-to-Treat multiple myeloma in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has returned or stopped responding to standard therapies. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and atta…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 26, 2026 05:35 UTC
-
Inside-Out attack: gene therapy builds cancer killers in the body
Disease control Recruiting nowThis early-stage trial tests a new gene therapy called KLN-1010 for people with multiple myeloma that has come back or not responded to treatment. The therapy works by giving a single injection that instructs the body's own immune cells to become cancer-fighting cells (CAR-T cell…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: Kelonia Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 05:34 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancer
Disease control Recruiting nowThis early study tests a new treatment called BCMA-UCART, which uses donor immune cells engineered to find and attack a protein (BCMA) on multiple myeloma cells. It is for adults whose cancer has returned or not responded to at least two prior treatments. The main goals are to ch…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: NA • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated May 26, 2026 05:29 UTC
-
New hope for elderly myeloma patients: talquetamab trial opens
Disease control Recruiting nowThis study tests a drug called talquetamab in elderly patients whose multiple myeloma has returned after initial treatment. The drug helps the body's immune cells attack cancer cells. If the drug stops working, another drug (daratumumab) may be added. The goal is to see if this a…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: Larysa Sanchez • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug cocktail targets Tough-to-Treat blood cancer
Disease control Recruiting nowThis study tests a combination of two drugs, belantamab mafodotin and venetoclax, with or without dexamethasone, in people whose multiple myeloma has come back or stopped responding to treatment. The trial focuses on patients with a specific genetic marker called t(11;14). The go…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo aims to deepen remissions in Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests whether adding the drug selinexor to standard bispecific antibody therapy can help people with relapsed or refractory multiple myeloma achieve deeper remission. About 27 adults who have already tried at least 4 prior treatments will take the combination for up to…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New Dual-Target CAR t therapy tackles Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called BCMA-CD19 cCAR for people with multiple myeloma or plasmacytoid lymphoma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target two proteins on cancer cells…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New cocktail aims to tame returning bone marrow cancer
Disease control Recruiting nowThis study tests whether adding daratumumab to a standard three-drug regimen can shrink tumors in people whose multiple myeloma has returned or stopped responding to prior treatments. About 43 adults aged 18 to 80 will receive the four drugs in cycles. The main goal is to see how…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: Andrew Yee, MD • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
Can early palliative care boost quality of life for blood cancer patients?
Symptom relief Recruiting nowThis study looks at whether adding early palliative care to usual treatment helps people with multiple myeloma or aggressive B-cell lymphoma feel better. About 144 patients and their caregivers will either get early palliative care plus standard care or standard care alone. Resea…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated May 22, 2026 14:05 UTC